

[x](#)

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
 - For example, a search on Aminosalicyclic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
 - A search for “Aminosalicyclic Acid Tablets” will result in anything that specifically contains “Aminosalicyclic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
 - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXORUBICIN ASSAY	USPNF Online	Online	26-Apr-2024	1-May-2024	NA	NA	In

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLOR IDE							<i>Proce dure/System suitability solution:</i> Add link to USP Store for USP Epirubicin Hydrochloride RS
DOXORUBICIN IM HYDROCHLOR PUR IDE FOR ITIES/ <i>Organic</i> INJECTION <i>Impurities</i>	USPNF Online Online		28-Oct-2022	1-Nov-2022	NA	NA	<i>In Analysis:</i> Change <i>P</i> = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: <i>P</i> = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
DOXORUBICIN ASSAY/ HYDROCHLOR <i>Procedure</i> IDE FOR INJECTION	USPNF Online Online		28-Oct-2022	1-Nov-2022	NA	NA	<i>In Analysis:</i> Change <i>P</i> = potency of doxorubicin in USP Doxorubicin

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXORUBICIN ASSAY/ HYDROCHLORIDE INJECTION	USPNF Online	Online	28-Oct-2022	1-Nov-2022	NA	NA	Hydrochloride RS (µg/mg) to: <i>P</i> = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) In <i>Analysis</i> : Change <i>P</i> = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: <i>P</i> = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) In <i>Analysis</i> : Change <i>P</i> = potency of doxorubicin in USP
DOXORUBICIN IM HYDROCHLORIDE INJECTION Purities/ Organic Impurities	USPNF 2022 Online	Online	28-Oct-2022	1-Nov-2022	NA	NA	Hydrochloride RS (µg/mg) In <i>Analysis</i> : Change <i>P</i> = potency of doxorubicin in USP

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXYCYCLINE CAPSULES	ADDITIONAL R EQUIREMENT <i>S/USP</i> <i>Reference</i> <i>Standards <11></i>	USPNF Online Online	24-Jun-2022	1-Jul-2022	NA	NA	Doxorubicin Hydrochloride RS (µg/mg) to: <i>P</i> = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4 <i>S</i> ,4 <i>aR</i> ,5 <i>S</i> ,5 <i>aR</i> ,6 <i>S</i> ,12 <i>aS</i>)-4-(Dimethylam ino)-1,4,4 <i>a</i> ,5,5 <i>a</i> ,6,11,12 <i>a</i> -octah ydro-3,5,10,12, 12 <i>a</i> -pentahydro xy-6-methyl-1,1 1-dioxo-2-napht

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXYCYCLINE FOR INJECTION	ADDITIONAL R EQUIREMENT <i>S/USP</i> <i>Reference</i> <i>Standards <11></i>	USPNF Online Online	24-Jun-2022	1-Jul-2022	NA	NA	hacenecarboxa mide monohydr ochloride. $C_{22}H_{24}N_2O_8 \cdot$ HCl 480.13 to: (4S,4aR,5S ,5aR,6S ,12aS)-4-(Dimethylam ino)-1,4,4a,5,5a ,6,11,12a-octah ydro-3,5,10,12, 12a-pentahydro xy-6-methyl-1,1 1-dioxo-2-napht hacenecarboxa mide hydrochloride. $C_{22}H_{24}N_2O_8 \cdot$ HCl 480.90 In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							(4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenenecarboxamide, monohydrochloride. $C_{22}H_{24}N_2O_8 \cdot HCl$ 480.13 to: (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenenecarboxamide hydrochloride. $C_{22}H_{24}N_2O_8 \cdot HCl$ 480.90

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description	
DOXYCYCLINE HYCLATE	CHEMICAL INFORMATION	USPNF Online	Online	27-May-2022	1-Jun-2022	NA	NA	Change 1025.87 to: 1025.88
DOXYCYCLINE HYCLATE	IMPURITIES/ <i>Organic Impurities</i>	USPNF Online	Online	27-May-2022	1-Jun-2022	NA	NA	In <i>Table 2</i> , footnote b: Change (4 <i>S</i> ,4 <i>aR</i> ,5 <i>S</i> ,5 <i>aR</i> ,6 <i>R</i> ,12 <i>aS</i>)-2-Acetyl-4-(di methylamino)-4 a,5a,6,12a-tetra hydro-3,5,10,12 ,12a-pentahydr oxy-6-methyl-tet racene-1,11-dio xo-2-naphthace necarboxamide. to: (4 <i>S</i> ,4 <i>aR</i> ,5 <i>S</i> ,5 <i>aR</i> ,6 <i>R</i> ,12 <i>aS</i>)-2-Acetyl-4-(di methylamino)-3, 5,10,12,12a-pe ntahydroxy-6-m ethyl-4a,5a,6,12 a-tetrahydrotetr ac ene-

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXYCYCLINE HYCLATE	ADDITIONAL R EQUIREMENT <i>S/USP</i> <i>Reference</i> <i>Standards <11></i>	USPNF Online Online	27-May-2022	1-Jun-2022	NA	NA	1,11(4 <i>H</i> ,5 <i>H</i>)-dione. In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change 480.13 to: 480.90
DOXYCYCLINE HYCLATE CAPSULES	ADDITIONAL R EQUIREMENT <i>S/USP</i> <i>Reference</i> <i>Standards <11></i>	USPNF Online Online	24-Jun-2022	1-Jul-2022	NA	NA	In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4 <i>S</i> ,4 <i>aR</i> ,5 <i>S</i> ,5 <i>aR</i> ,6 <i>S</i> ,12 <i>aS</i>))-4-(Dimethylam ino)-1,4,4 <i>a</i> ,5,5 <i>a</i> ,6,11,12 <i>a</i> -octah

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXYCYCLINE ADDITIONAL REQUIREMENT HYCLATE DEL EQUIREMENT AYED- RELEASE TABLETS	USPNF Online Online <i>SIUSP</i> <i>Reference</i> <i>Standards <11></i>		24-Jun-2022	1-Jul-2022	NA	NA	ydro-3,5,10,12, 12a-pentahydro xy-6-methyl-1,1 1-dioxo-2-napht hacenecarboxa mide, monohydr ochloride. C ₂₂ H ₂₄ N ₂ O ₈ · HCl 480.13 to: (4S,4aR,5S ,5aR,6S ,12aS)-4-(Dimethylam ino)-1,4,4a,5,5a ,6,11,12a-octah ydro-3,5,10,12, 12a-pentahydro xy-6-methyl-1,1 1-dioxo-2-napht hacenecarboxa mide hydrochloride. C ₂₂ H ₂₄ N ₂ O ₈ · HCl 480.90 In USP Doxycycline Related Compound A RS: Change 444.43

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							to: 444.44 AND Change (4S,4aR,5S ,5aR,6S ,12aS)-4-(Dimethylam ino)-1,4,4a,5,5a ,6,11,12a-octah ydro-3,5,10,12, 12a-pentahydro xy-6-methyl-1,1 1-dioxo-2-napht hacenecarboxa mide, monohydr ochloride. C₂₂H₂₄N₂O₈ · HCl 480.13 to: (4S,4aR,5S ,5aR,6S ,12aS)-4-(Dimethylam ino)-1,4,4a,5,5a ,6,11,12a-octah ydro-3,5,10,12, 12a-pentahydro xy-6-methyl-1,1 1-dioxo-2-napht hacenecarboxa

Monograph Title __Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXYCYCLINE HYCLATE TABLETS	ADDITIONAL R EQUIREMENT <i>S/USP</i> <i>Reference</i> <i>Standards <11></i>	USPNF Online	Online	24-Jun-2022	1-Jul-2022	NA	NA	mide hydrochloride. C₂₂H₂₄N₂O₈ · HCl 480.90 In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4S,4aR,5S ,5aR,6S ,12aS)-4-(Dimethylam ino)-1,4,4a,5,5a ,6,11,12a-octah ydro-3,5,10,12, 12a-pentahydro xy-6-methyl-1,1 1-dioxo-2-napht hacenecarboxa mide, monohydr ochloride. C₂₂H₂₄N₂O₈ · HCl 480.13 to: (4S,4aR,5S

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXYCYCLINE TABLETS	ADDITIONAL R EQUIREMENT S/USP Reference Standards <11>	USPNF Online Online	24-Jun-2022	1-Jul-2022	NA	NA	,5aR,6S ,12aS)-4-(Dimethylam ino)-1,4,4a,5,5a ,6,11,12a-octah ydro-3,5,10,12, 12a-pentahydro xy-6-methyl-1,1 1-dioxo-2-napht hacenecarboxa mide hydrochloride. C ₂₂ H ₂₄ N ₂ O ₈ · HCl 480.90 In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4S,4aR,5S ,5aR,6S ,12aS)-4-(Dimethylam ino)-1,4,4a,5,5a ,6,11,12a-octah ydro-3,5,10,12,

Monograph TitleSection __Sort descending__	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DUTASTERIDE PERFORMANCE AND TAMSULOSIN HYDROCHLORIDE CAPSULES	USPNF Online	Online	17-Nov-2023	1-Dec-2023	NA	NA	12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenenecarboxamide, monohydrochloride. C ₂₂ H ₂₄ N ₂ O ₈ · HCl 480.13 to: (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenenecarboxamide hydrochloride. C ₂₂ H ₂₄ N ₂ O ₈ · HCl 480.90 In <i>Dissolution</i> ?711?/Test for dutasteride/Tier 2/Medium: Change 10 g/L of cetyltrimethylammoniu

Monograph TitleSection __Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DUTASTERIDE ADDITIONAL R AND EQUIREMENT TAMSULOSIN S HYDROCHLOR IDE CAPSULES	USPNF Online Online		17-Nov-2023	1-Dec-2023	NA	NA	m bromide and 750,000 USP units of activity/mg of pepsin, purified in 0.1 N hydrochloric acid; 900 mL to: Dissolve 10 g of cetyltrimethylam monium bromide and 1.6 g of pepsin, purified in 1000 mL of 0.1 N hydrochloric acid; 900 mL In <i>USP</i> <i>Reference</i> <i>Standards</i> ?11?/USP Dihy drodutasteride RS: Change N -[2,5-Bis(trifluor omethyl)phenyl] -3-oxo-4-aza-5? -androst-1-ene- 17?- carboxamide.

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ECONAZOLE NITRATE	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	USPNF Online	Online	26-Aug-2022	1-Sep-2022	NA	USPNF 2023 Issue 2	to: N -[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androstane-17?-carboxamide. In USP Econazole Related Compound C RS: Change 1-(4-Chlorobenzyl)-3-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)-1H-imidazol-3-ium nitrate (salt). C₂₅H₂₁Cl₁₄N₃O₄ 569.26 to: 1-(4-Chlorobenzyl)-3-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)-1H-imidazol-3-ium chloride.

Monograph Title __Sort descending__	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ENSULIZOLE	IDENTIFICATION	USPNF Online	Online	29-Mar-2024	1-Apr-2024	NA	NA	C₂₅H₂₁Cl₅N₂O 542.71 In <i>B.</i>: Change The retention time of the major peak of the <i>Sample solution</i> exhibits maxima and minima at the same wavelengths as those of the <i>Standard solution</i>, as obtained in the Assay. to: The retention time of the major peak of the <i>Sample solution</i> corresponds to that of the <i>Standard solution</i>, as obtained in the Assay.
ENZACAMENE	ASSAY/ Procedure	USPNF Online	Online	28-Oct-2022	1-Dec-2022	NA	NA	In <i>Analysis</i>: Change

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ERYTHROMYCIN PERFORMANC IN DELAYED- RELEASE TABLETS	USPNF Online E TESTS/ <i>Dissolution</i> ?711?	Online	31-Mar-2023	1-Apr-2023	NA	NA	C_U = concentration of enzacamene in the <i>Sample</i> <i>solution</i> (mg/mL) to: C_U = concentration of Enzacamene in the <i>Sample</i> <i>solution</i> (mg/mL) In <i>Test 1</i>: Change Buffer stage Medium: 0.05 M pH 6.8 phosphate buffer (see <i>Reagents,</i> <i>Indicators, and</i> <i>Solutions—Buffer</i> <i>Solutions</i>) to: Buffer stage Medium: 0.05 M pH 6.8 phosphate buffer (see

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ERYTHROMYCIN IDENTIFICATION IN ETHYLSUCCINATE FOR ORAL SUSPENSION	USPNF Online	Online	31-Mar-2023	1-Apr-2023	NA	NA	Reagents, Indicators, and Solutions—Buffer Solutions); 900 mL Change Proceed as directed in the Identification test under Erythromycin Ethylsuccinate Oral Suspension, beginning with “Prepare a Standard solution.” to: Prepare a Standard solution of USP Erythromycin Ethylsuccinate RS in methanol containing about 3 mg per mL. Apply separately 10 µL each of the test solution

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							and the Standard solution to a suitable thin-layer chromatographic plate (see <i>Chromatography</i> ?621?) coated with a 0.25-mm layer of chromatographic silica gel mixture, and allow to dry. Place the plate in an unlined chromatographic chamber, and develop the chromatograms in a solvent system consisting of a mixture of methanol and chloroform (85:15) until the solvent front has moved about 9 cm. Remove the

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							plate from the chamber, mark the solvent front, and allow the solvent to evaporate. Spray the plate with a mixture of dehydrated alcohol, <i>p</i>-methoxybenzal dehyde, and sulfuric acid (90:5:5). Heat the plate at 100° for 10 minutes, and examine the chromatograms, in which the erythromycin and succinic acid moieties appear as black-to-purple spots: the R_F values of the principal spots obtained from the test solution correspond to

Monograph TitleSection __Sort descending__	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ERYTHROMYCIN ASSAY IN ETHYLSUC- CINATE FOR ORAL SUSPENSION	USP-NF Online	Online	31-Mar-2023	1-Apr-2023	NA	NA	those obtained from the Standard solution. Change Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed in the Assay under <i>Erythromycin Ethylsuccinate Oral Suspension</i> . to: Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed for erythromycin under

Monograph Title Section __Sort descending__	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<i>Antibiotics—Microbial Assays</i> ?81?, using an accurately measured volume of the reconstituted suspension, freshly mixed and free from air bubbles, blended for 4 ± 1 minutes in a high-speed glass blender jar with sufficient methanol to give a stock solution containing the equivalent of about 1 mg of erythromycin per mL. Dilute this stock solution quantitatively with <i>Buffer B.3</i> to obtain a <i>Test Dilution</i> having

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ESCITALOPRA ASSAY/ M TABLETS <i>Procedure</i>	USPNF Online	Online	28-Apr-2023	1-May-2023	NA	NA	a concentration assumed to be equal to the median dose level of the Standard. In <i>Buffer</i> : Change Adjust with 1 N sodium hydroxide VS to a pH of 5.2. to: Adjust with 1 N sodium hydroxide to a pH of 5.2.
ESCITALOPRA PERFORMANC M TABLETS E TESTS/ <i>Dissolution</i> <i>?711?</i>	USPNF Online	Online	28-Apr-2023	1-May-2023	NA	NA	In <i>Test 1/Medium</i> : Change 0.1 N hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL AND In <i>Test 2/Medium</i> :

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FELODIPINE	IM PUR ITIES/ <i>Organic</i> <i>Impurities</i>	<i>USPNF Online</i> Online	18-Nov-2022	1-Dec-2022	NA	NA	Change 0.1 N hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL Change Buffer, Mobile phase, System suitability solution, Standard solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay. to: Buffer, Mobile phase, System suitability solution, Standard solution n

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description	
FLUOCINOLON E ACETONIDE	Organic Impurities	USPNF Online	Online	27-May-2022	1-Jun-2022	NA	NA	, Sample solution, and Chromatographic system: Proceed as directed in the Assay, and use 40 µL injection volume for the <i>Sensitivity solution</i>. In <i>Acceptance criteria</i> <i>Total impurities</i>: Change NMT 2.5%. Disregard any peak below 0.05% of the peak area of fluocinolone acetonide from the <i>Standard solution</i>. to: NMT 2.5%. Disregard any peak below 0.05% of the peak area of fluocinolone

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLURAZEPAM USP HYDROCHLORIDE REFERENCE STANDARDS ?11?	USPNF Online	Online	23-Feb-2024	1-Mar-2024	NA	NA	acetone from the <i>Sample</i> <i>solution</i> . In USP Flurazepam Related Compound C RS: Change 5-Chloro-2-(2-di ethylaminoethyl (amino)-2'-fluor obenzophenone hydrochloride. to: 5-Chloro-2-(2-di ethylaminoethyl amino)-2'-fluor obenzophenone hydrochloride.
FLUTICASONE IM PROPIONATE PUR NASAL SPRAY ITIES/ <i>Organic</i> <i>Impurities</i>	USPNF Online	Online	27-Jan-2023	1-Feb-2023	NA	NA	In <i>Analysis</i> : Change Samples: <i>System</i> <i>suitability</i> <i>solution</i> , <i>Identification</i> <i>solution</i> , and <i>Sample solution</i> to: Samples: <i>Identification</i>

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUTICASONE OTHER COMP PROPIONATE ONE NASAL SPRAY NTS/ <i>Content of</i> <i>Phenylethyl</i> <i>Alcohol</i>	USPNF Online	Online	28-Apr-2023	1-May-2023	NA	NA	<i>solution and</i> <i>Sample solution</i> In <i>Sample</i> <i>solution</i> : Change Transfer 1.0 g of the Nasal Spray to a 50-mL volumetric flask. Add about 40 mL of <i>Diluent</i> , and sonicate for 10 min until the supernatant is clear. Use the clear supernatant for analysis. to: Transfer 1.0 g of the Nasal Spray to a 50-mL volumetric flask. Add about 40 mL of <i>Diluent</i> , and sonicate for 10 min. Dilute with <i>Diluent</i> to volume, and

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUVOXAMINE ASSAY/ MALEATE Procedure TABLETS	USPNF Online Online		28-Apr-2023	1-May-2023	NA	NA	shake. Allow to stand for 10 min until the supernatant is clear. Use the clear supernatant for analysis. In <i>Solution A</i> : Change 8 g/L of 1-penta nesulfonic acid sodium salt and 1 g/L of monobasic potassium phosphate in water. to: 8 g/L of 1-penta nesulfonic acid sodium salt and 1.1 g/L of monobasic potassium phosphate in water.
FORSKOHLII COMPOSITION /Content of Forskolin	USPNF Online Online		29-Jul-2022	1-Aug-2022	NA	NA	In <i>Chromatographi c system</i> : Change

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOSAMPRENA PERFORMANCE VIR CALCIUM E TESTS TABLETS	USPNF Online	Online	25-Aug-2023	1-Sep-2023	NA	NA	Column: 4.6-mm × 25-cm; 5-μm, 100 Å to: Column: 4.6-mm × 25-cm; 5-μm, 100 Å; packing L1 In <i>Dissolution</i> ?711?/Medium: Change 26.7 g/L of sodium acetate trihydrate in water. Add 133 mL of glacial acetic acid to this solution, and then dilute with water to 10 L; 900 mL. to: 0.02 M sodium acetate buffer, pH 3.5, prepared as follows. Dissolve 2.67 g of sodium

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GLUCAGON	PROCESS-RELATED IMPURITIES AND OTHER COMPONENTS	USPNF Online Online	29-Dec-2023	1-Jan-2024	NA	NA	acetate in 100 mL of water. Add 13.3 mL of glacial acetic acid and then dilute with water to 1000 mL; 900 mL. In <i>Acetic Acid in Peptides/Analysis</i>: Change C_{SPA} = concentration of potassium acetate in each of the <i>Standard solutions</i> (mg/mL) to: C_{SPA} = concentration of potassium acetate in each of the <i>Standard solutions</i> (µg/mL) AND In <i>Ammonium/</i>

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GLYCYL-L-TYROSINE	IM PUR ITIES/ <i>Related Compounds</i>	USPNF Online Online	24-Feb-2023	1-Jun-2023	NA	NA	<i>Analysis:</i> Change C_{SAC} = concentration of ammonium chloride in each of the <i>Standard solutions</i> (mg/mL) to: C_{SAC} = concentration of ammonium chloride in each of the <i>Standard solutions</i> (µg/mL) In <i>Buffer solution</i>: Change Dissolve 6.84 g of potassium phosphate in 1000 mL of water. to: Dissolve 6.84 g of monobasic potassium phosphate in 1000 mL of

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HOMATROPIN CHEMICAL E HYDROBRO INFORMATION MIDE	USPNF Online	Online	24-Jun-2022	1-Jul-2022	NA	NA	water. Change 356.25 to: 356.26 AND Change 1?H,5?H- Tropan-3?-ol mandelate (ester) hydrobromide to: (1 <i>R</i> ,3 <i>r</i> ,5 <i>S</i>) -8-Methyl-8-az abicyclo[3.2.1]o ctan-3-yl 2-hydr oxy-2-phenylac etate hydrobromide In <i>Buffer</i> : Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1.
HYDROCODONE NE BITARTRATE AND HOMATR OPINE METHY LBROMIDE TABLETS	USPNF Online	Online	24-Jun-2022	1-Jul-2022	NA	NA	hydrobromide In <i>Buffer</i> : Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1.

Monograph Title __Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS	IMPURITIES/ <i>Limit of Homatropine Hydrobromide and Related Substances</i>	USPNF Online	Online	24-Jun-2022	1-Jul-2022	NA	NA	In <i>Buffer</i> : Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1.
IBUPROFEN ORAL SUSPENSION	PERFORMANCE TESTS/ <i>Dissolution</i> <711>	USPNF Online	Online	27-May-2022	1-Jun-2022	NA	NA	In <i>Analysis</i> : Change Result = $(R_U/R_S) \times C_S \times V$ $\times (D/W_U) \times (1/L)$ $\times 100$ R_U = peak area ratio of ibuprofen to benzophenone from the <i>Sample solution</i> R_S = peak area ratio of ibuprofen to benzophenone from the <i>Standard solution</i> C

Monograph TitleSection __Sort descending__	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							S= concentration of USP Ibuprofen RS in the <i>Standard solution</i> (mg/mL) V = volume of <i>Medium</i>, 900 mL D = density of Oral Suspension (g/mL) W_U = weight of the portion of Oral Suspension added to the <i>Medium</i> (g) L = label claim (mg/mL) to: Result = $(R_U/R_S) \times C_S \times V$ $\times (d/W_U) \times D \times$ $(1/L) \times 100$ R_U = peak area ratio of ibuprofen to benzophenone

Monograph TitleSection __Sort descending__	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							from the <i>Sample solution</i> R_S = peak area ratio of ibuprofen to benzophenone from the <i>Standard solution</i> C_S = concentration of USP Ibuprofen RS in the <i>Standard solution</i> (mg/mL) V = volume of <i>Medium</i>, 900 mL d = density of Oral Suspension (g/mL) W_U = weight of the portion of Oral Suspension added to the <i>Medium</i> (g) D = dilution factor of the

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IODIXANOL INJECTION	IMPURITIES	USPNF Online Online	23-Feb-2024	1-Mar-2024	NA	NA	Sample solution, 2 L = label claim (mg/mL) In <i>Organic Impurities, Procedure 2/footnote 4:</i> Change 5-[[[3-[[[3-[[[3-[[[3-[[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl](acetylmino)]-2-hydroxypropyl](acetylmino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]carbonyl]amino]-2-hydroxypropyl]oxy]-2-hydroxypropyl](acetylmino)]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzendicarboxamide.

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							to: 5-[[3-[[3-[[[3-[[3 -[[3,5-Bis-[[[2,3- dihydroxypropyl]amino]carbonyl]-2,4,6-triiodoph enyl](acetylamin o)]-2-hydroxypr opyl](acetylamin o)]-5-[[[2,3-dihy droxypropyl]ami no]carbonyl]-2,4 ,6-triiodophenyl] carbonyl]amino] -2-hydroxypropy l]oxy]-2-hydroxy propyl](acetyla mino)]-N,N '-bis(2,3-dihydro xypropyl)-2,4,6-t riiodo-1,3-benze ndicarboxamide ' In <i>USP</i> <i>Reference</i> <i>Standards</i> ?11?/USP Iodixanol Related Compound E RS: Change
IODIXANOL INJECTION	ADDITIONAL R EQUIREMENT S	<i>USPNF Online</i> Online	23-Feb-2024	1-Mar-2024	NA	NA	

Monograph TitleSection __Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IPRATROPIUM IMPURITIES BROMIDE INHALATION SOLUTION	USPNF Online Online		29-Mar-2024	1-Apr-2024	NA	NA	5-[[3-[[3-[[[(2,3-Dihydroxypropyl)amino]carbonyl]-5- [[amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl)-(acetylimino)]-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide. to: 5-{N-[3-(N-{3-Carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-N ¹ ,N ³ -bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide. In <i>Organic Impurities</i> : Change Column:

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description	
IRINOTECAN H YDROCHLORI DE INJECTION	USPNF Online	Online	26-Aug-2022	1-Sep-2022	NA	NA	4.6-mm × 25-μm; 5-μm packing L1 to: Column: 4.6-mm × 25-cm; 5-μm packing L1 Change NTL 90.0% and NMT 110.0% to: NLT 90.0% and NMT 110.0%	
ISOBUTYL ALCOHOL	ASSAY/ Procedure	USPNF Online	Online	27-Jan-2023	1-Feb-2023	NA	NA	In <i>Analysis</i> : Change r_S = sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the <i>Reference</i> <i>solution</i> to: r_T = sum of all the peaks except those

Monograph Title __Sort descending__	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOFLURANE	IM PUR ITIES/ <i>Organic Impurities</i>	USPNF Online	Online	28-Apr-2023	1-May-2023	NA	NA	each of which with an area less than 0.1 times the area of the major peak from the <i>Reference solution</i> In <i>Analysis</i>: Change Result = $(r_U/r_S) \times C_S \times (1/F)$ to: Result = $(r_U/r_S) \times C_F \times (1/F)$ AND Change C_S = final concentration of USP Isoflurane Related Compound B RS in the <i>Standard solution</i> (%) to: C_F = final concentration of USP Isoflurane Related Compound B

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOSORBIDE MONONITRAT E TABLETS	IMPURITIES <i>USPNF Online</i>	Online	26-Apr-2024	1-May-2024	NA	NA	RS in the <i>Standard solution (%)</i> In <i>Organic Impuri ties/Standard solution:</i> Change isosorbide related compound A to: isosorbide mon onitrate related compound A AND In <i>System suitabil ity/Suitability re quire ments/Relative standard deviation:</i> Change isosorbide related compound A, to: isosorbide mon onitrate related

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IVERMECTIN	CHEMICAL INFORMATION	USPNF Online Online	24-Jun-2022	1-Jul-2022	NA	NA	compound A, AND In four instances in <i>Analysis</i>: Change isosorbide related compound A, to: isosorbide mon onitrate related compound A, AND In <i>Table 1</i>: Change Isosorbide related compound A to: Isosorbide mon onitrate related compound A Change C₄₈H₇₄O₁₄ (Component H₂B_{1a}) 875.09 C₄₇H₇₂O₁₄ (Component H₂B_{1b}) 861.07 Component

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							H ₂ B _{1a} : Avermectin A _{1a} , 5- <i>O</i> -demethyl-22,23 -dihydro- (2a <i>E</i> ,4 <i>E</i> ,8 <i>E</i>)-(5? <i>S</i> ,6 <i>S</i> ,6? <i>R</i> ,7 <i>S</i> ,11 <i>R</i> ,13 <i>R</i> ,15 <i>S</i> ,17a <i>R</i> ,20 <i>R</i> ,20a <i>R</i> ,20b <i>S</i>)-6?-(<i>S</i>)-sec -Butyl-3?,4?,5?, 6,6?,7,10,11,14, 15,17a,20,20a,2 0b-tetradecahyd ro-20,20b-dihyd roxy[11,15-meth ano-2 <i>H</i> ,13 <i>H</i> ,17 <i>H</i> -furo[4,3,2- <i>pq</i>][2,6]benzodiox acyclooctadecin -13,2?- [2 <i>H</i>]pyran]-7-yl 2, 6-di deoxy- 4- <i>O</i>

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							O -me thyl-?- L- <i>arabino</i> -hexopyranosyl) -3-O-methyl-?- L- <i>arabino</i> -hexopyranosid e CAS RN®: 70161-11-4. Component H₂B_{1b}: Avermectin A_{1a}, 5-O -demethyl-25-d e(1-methylpropy l)-22,23-dihydro -25-(1-methylet hyl)-. (2aE,4E,8E)-(5?S,6S,6?R ,7S,11R,13R ,15S,17aR ,20R,20aR ,20bS)-3?,4?,5?,6,6?, 7,10,11,-oxospir o[11,15-methan

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							o-2 <i>H</i> ,13 <i>H</i> ,17 <i>H</i> -furo[4,3,2- <i>pq</i>][2,6]benzodiox acyclooctadecin -13,2?[2 <i>H</i>]pyran]-7-yl 2, 6-di deoxy- 4- <i>O</i>
							<i>O</i> -me thyl-?- L- <i>arabino</i> -hexopyranosyl) -3- <i>O</i> -methyl-?- L- <i>arabino</i> -hexopyranosid e CAS RN®: 70209-81-3; UNII: 0W28CYI3TU. to: C ₄₈ H ₇₄ O ₁₄ (Component H

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							² B _{1a}) 875.11 C ₄₇ H ₇₂ O ₁₄ (Component H ₂ B _{1b}) 861.08 Component H ₂ B _{1a} : Avermectin A _{1a} , 5-O -demethyl-22,23 -dihydro- (2aE,4E,8E)-(5'S,6S,6'R ,7S,11R,13R ,15S,17aR ,20R,20aR ,20bS)-6'-(S)- sec -Butyl-3',4',5', 6,6',7,10,11,14, 15,17a,20,20a,2 0b-tetradecahyd ro-20,20b-dihyd roxy-5',6,8,19-t etramethyl-17-o xospiro [11,15- meth ano-2H,13H ,17H -furo[4,3,2-pq][2,6]benzodiox

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							acyclooctadecin -13,2'-[2 <i>H</i>]pyran]-7-yl 2, 6-di deoxy- 4- <i>O</i>
							<i>O</i> -me thyl-?- L- <i>arabino</i> -hexopyranosyl) -3- <i>O</i> -methyl-?- L- <i>arabino</i> -hexopyranosid e CAS RN®: 71827-03-7; UNII: 91Y2202OUW. Component H ₂ B _{1b} : Avermectin A _{1a} , 5- <i>O</i> -demethyl-25-d e(1-methylpropy l)-22,23-dihydro -25-(1-methylet

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							hyl)-. (2aE,4E,8E)-(5'S,6S,6'R ,7S,11R,13R ,15S,17aR ,20R,20aR ,20bS)-3',4',5',6,6', 7,10,11,14,15,1 7a,20,20a,20b- Tetradecahydro -20,20b-dihydro xy-6'-isopropyl- 5',6,8,19-tetra methyl-17-oxos piro [11,15-met hano-2 <i>H</i> ,13 <i>H</i> ,17 <i>H</i> -furo[4,3,2- <i>pq</i>][2,6]benzodiox acyclooctadecin -13,2'-[2 <i>H</i>]pyran]-7-yl 2, 6-di deoxy- 4- <i>O</i> O

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LANSOPRAZOLE DELAYED-RELEASE CAPSULES LATANOPROST	IM PURITIES/ <i>Organic Impurities</i> ASSAY/ <i>Procedure</i>	USPNF Online Online	30-Sep-2022	1-Oct-2022	NA	NA	-me thyl-?- L- <i>arabino</i> -hexopyranosyl) -3-O-methyl-?- L- <i>arabino</i> -hexopyranosid e CAS RN®: 70209-81-3; UNII: 0W28CYI3TU. Delete Blank: Methanol and <i>Diluent</i> (1:9) Change Standard solution: Transfer 2.0 mg/mL of USP Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final

Monograph Title Section __Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							volume, and dilute with chromatographic hexane to volume. Sample solution: Transfer 2.0 mg/mL of Latanoprost into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chromatographic hexane to volume. to: Standard solution: 2.0 mg/mL of USP Latanoprost RS prepared as follows. Transfer USP

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chromatographic hexane to volume. Sample solution: 2.0 mg/mL of Latanoprost prepared as follows. Transfer Latanoprost into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chromatographic

Monograph Title Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEVORPHANO L TARTRATE TABLETS	PERFORMANC E TESTS/ <i>Uniformity of Dosage Units</i> ?905?	USPNF Online Online	31-Mar-2023	1-Aug-2023	NA	NA	hexane to volume. In <i>Sample solution</i> : Change Nominally about 80 ug/mL of levorphanol tartrate in <i>Diluent</i> prepared as follows. to: Nominally about 80 µg/mL of levorphanol tartrate in <i>Diluent</i> prepared as follows.
LIDOCAINE	ASSAY	USPNF Online Online	29-Mar-2024	1-Apr-2024	NA	NA	In <i>Procedure</i> : Change Column: 3.9-mm × 30-cm; 4-µm packing L1 to: Column: 3.9-mm × 30-cm; 10-µm

Monograph TitleSection __Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							packing L1

Pagination

- [_First page « First](#)
- [_Previous page < Previous](#)
- [_Page 1](#)
- [_Page 2](#)
- [_Current page 3](#)
- [_Page 4](#)
- [_Page 5](#)
- [_Page 6](#)
- [_Next page Next >](#)
- [_Last page Last »](#)